Beranda › Leukemia Biphenotypic Akut › Wisconsin
Uji klinis Leukemia Biphenotypic Akut di Wisconsin
5 studi untuk Leukemia Biphenotypic Akut mencari peserta di lokasi di Wisconsin.
Kota di Wisconsin
Teks studi resmi (Bahasa Inggris)
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- Children's Hospital of Wisconsin, Milwaukee
Menerima pesertaFase 2
365 Days · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06317662Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Saint Vincent Hospital Cancer Center Green Bay, Green Bay
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
- dan 1 lainnya
Menerima pesertaFase 3
365 Days – 25 Years · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
- Marshfield Medical Center-Marshfield, Marshfield
Menerima pesertaFase 1/2
Hingga usia 22 · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT04726241MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
- Children's Wisconsin, Milwaukee
Menerima peserta
Usia 0 hingga 25 · Semua jenis kelamin · Diperbarui 13 Mei 2026 · NCT05794880Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Hospital of Wisconsin, Milwaukee
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.